Monday , November 30 2020

Russia assured that its coronavirus vaccine will be cheaper than competitors Pfizer and Moderna

Bottle jars with label "Sputnik-V" in Tver, Russia, October 12, 2020. REUTERS / Tatyana Makeyeva
Bottle jars marked “Sputnik-V” in Tver, Russia, October 12, 2020. REUTERS / Tatyana Makeyeva

Those responsible for the production of the Russian vaccine Sputnik V against the coronavirus have on Sunday assured that the drug price will be lower than the competitors Pfizer and Moderna. “Pfizer’s advertised price is $ 19.50 and Modern is between $ 25-37 per dose, but in reality it means a cost of $ 39 and $ 50-74 per person.”, they explain in a message from their Twitter account picked up by the Russian news agency Sputnik.

Because “two doses per person are required for the Pfizer, Sputnik V and Moderna vaccines. The price of Sputnik V will be much lower “, they concluded in the announcement.

Hours before, The CEO of the American pharmaceutical company Moderna, Stéphane Bancel, had announced that the price of his product would be between 25 and 37 dollars per dose, according to commented to “Welt am Sonntag”. “It is a reasonable price given the burden on health care every serious case of COVID-19. For us, it is not a question of profit “, assured the CEO before clarifying that the final price depends on the volume of each specific contract.

Bancel has added it Modern intends to manufacture 20 million doses of vaccine for the rest of the year and that “a small part” will be available to European countries as early as this year. “At the moment we have not signed anything but we are close to reaching an agreement with the European Commission. We want to supply Europe (with the vaccine) and we are conducting constructive negotiations, he revealed.

What stage is Sputnik V at? According to Denis Lugunov, head of the Gamaleya Center and a member of the Russian Academy of Sciences, which leads the group of developers of the Russian vaccine, 20 thousand people have received the first dose and 14 thousand people go for the second: “Until we have received the results of the research, we can not estimate what long-term effect the vaccine will have. We hope to have a long-lasting effect but we know it in time.”.

A doctor at a Russian regional hospital in Tver receives the vaccine "Sputnik-V" against the new coronavirus in Tver, Russia, October 12, 2020. REUTERS / Tatyana Makeyeva / Filfoto
A doctor at a Russian regional hospital in Tver receives the vaccine “Sputnik-V” against the new coronavirus in Tver, Russia, on October 12, 2020. REUTERS / Tatyana Makeyeva / Filfoto

“What we observed in the progress of our colleagues, because we had a conference where those from Pfizer, those from Oxford, Sinopharm were present, is that they all have the same principle: they are very similar and all producers reached phase III synchronously. , they are all very similar, but the key parameter stands out in which vaccine is most effective. We will see that result in a very short time. Until we get the results, we can not talk about the benefits of one independent vaccine over the other, Lugunov stressed.

The pandemic forced researchers to experiment with the emergence of the new disease. As a result, times accelerated. “No one knows how long the immunity will be because we started the testing process four months ago. We have experience with Ebola and MERS but we can not take it as a parameter. By the end of the year, we will be able to have the checkpoint because we will have reached six months, ”Lugunov pointed out.

Regarding new adverse effects observed in this new stage, The professionals explained that they did not vary from the first phases: injection site pain, headache, fever, injection site redness, but there were no serious or moderate complications.

Artificially created, without any element of the coronavirus in its composition, the vaccine is presented in lyophilized form, i.e. as a powder which is mixed with an excipient to dissolve it and then administered intramuscularly.


Sputnik V uses a human adenovirus technique of two different vectors, Ad5 and Ad26, for a first and a second injection. And its biggest approval had been developed, in 2015, to treat Ebola, which passed all phases of clinical trials and was used to defeat the disease epidemic in Africa in 2017.

However, Sputnik V does not contain live human adenoviruses, but human adenoviral vectors that cannot multiply and are reportedly safe for health. Other laboratories also use human adenoviral vector-based platforms for their COVID-19 vaccines, such as Johnson & Johnson, which uses the Ad26 vector only, and China’s CanSino, which uses only Ad5.

Continue reading:

The FDA approved the Regeneron treatment that Trump used to fight covid-19

The UK is preparing a system of regional restrictions that will replace the lock-in from December

Why the arrival of a vaccine is only the beginning of the road to a new normal

Source link